These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8263315)

  • 21. Serum testosterone levels are related to cognitive function in men with schizophrenia.
    Moore L; Kyaw M; Vercammen A; Lenroot R; Kulkarni J; Curtis J; O'Donnell M; Carr VJ; Shannon Weickert C; Weickert TW
    Psychoneuroendocrinology; 2013 Sep; 38(9):1717-28. PubMed ID: 23490072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).
    Wu XL; Wang JH; Hu SH; Tao J
    East Asian Arch Psychiatry; 2012 Mar; 22(1):7-11. PubMed ID: 22447799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolactin responses to domperidone in chronic schizophrenia.
    Nerozzi D; Magnani A; Dastoli C; Ferri E; Capesciotti G; Antonozzi I; Frajese G; Meltzer HY
    Psychiatry Res; 1992 May; 42(2):159-69. PubMed ID: 1631251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risperidone added to clozapine: impact on serum prolactin levels.
    Henderson DC; Goff DC; Connolly CE; Borba CP; Hayden D
    J Clin Psychiatry; 2001 Aug; 62(8):605-8. PubMed ID: 11561931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. The Scottish Schizophrenia Research Group.
    Br J Psychiatry; 1987 Mar; 150():334-8. PubMed ID: 2889495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma prolactin concentrations and psychopathology in chronic schizophrenia.
    Kleinman JE; Weinberger DR; Rogol AD; Bigelow LB; Klein ST; Gillin JC; Wyatt RJ
    Arch Gen Psychiatry; 1982 Jun; 39(6):655-7. PubMed ID: 6979991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MCPP challenge test in schizophrenia: hormonal and behavioral responses.
    Iqbal N; Asnis GM; Wetzler S; Kahn RS; Kay SR; van Praag HM
    Biol Psychiatry; 1991 Oct; 30(8):770-8. PubMed ID: 1751620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
    Westheide J; Cvetanovska G; Albrecht C; Bliesener N; Cooper-Mahkorn D; Creutz C; Hornung WP; Klingmüller D; Lemke MR; Maier W; Schubert M; Sträter B; Kühn KU
    J Sex Med; 2008 Dec; 5(12):2816-26. PubMed ID: 18466271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
    Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
    Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between prolactin and thyroid hormones with severity of psychopathology and suicide risk in drug free male schizophrenia.
    Jose J; Nandeesha H; Kattimani S; Meiyappan K; Sarkar S; Sivasankar D
    Clin Chim Acta; 2015 Apr; 444():78-80. PubMed ID: 25677864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
    Csernansky JG; Kaplan J; Holman CA; Hollister LE
    Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Antipsychotics on Bone Mineral Density and Sex Hormones in Male Patients with Schizophrenia.
    Bulut SD; Bulut S; Atalan DG; Tulaci RG; Türker T; Gürçay E; Aydemir Ç
    Psychiatr Danub; 2016 Sep; 28(3):255-262. PubMed ID: 27658834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 24-hour plasma levels of prolactin, cortisol, growth hormone and catecholamines in schizophrenic patients.
    Kemali D; Maj M; Ariano MG; Arena F; Lovero N
    Neuropsychobiology; 1985; 14(3):109-14. PubMed ID: 3831798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes.
    Segal M; Avital A; Rojas M; Hausvater N; Sandbank S; Liba D; Moguillansky L; Tal I; Weizman A
    Psychiatry Res; 2004 Jul; 127(3):227-35. PubMed ID: 15296822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormonal effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolactin shifts after neuroleptic withdrawal.
    Green AI; Faraone SV; Brown WA
    Psychiatry Res; 1990 Jun; 32(3):213-9. PubMed ID: 1975101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine.
    Nakonezny PA; Byerly MJ; Rush AJ
    J Sex Marital Ther; 2007; 33(3):203-16. PubMed ID: 17454518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients.
    Keks NA; McKenzie DP; Low LH; McGorry PD; Hill C; Kulkarni J; Singh BS; Copolov DL
    Biol Psychiatry; 1992 Sep; 32(5):426-37. PubMed ID: 1486148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
    Elizur A; Segal Z; Yeret A; Ben-David M
    Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
    [No Abstract]   [Full Text] [Related]  

  • 40. Relationship of psychotic symptoms to haloperidol-stimulated prolactin release.
    Kulkarni J; Keks NA; Stuart G; Mackie B; Minas IH; Singh BS; Copolov DL
    Acta Psychiatr Scand; 1990 Oct; 82(4):271-4. PubMed ID: 2260479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.